Clinical trials: Intravitreal Injection
Diabetic Macular Edema
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
The purpose of this study is to evaluate the pharmacokinetics, safety and preliminary efficacy of 3 doses of Cand5. Cand5 is a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
- Trial name
- NCT00306904
- Testing
- bevasiranib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- OPKO Health, Inc.
Macular Degeneration
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of free and vascular endothelial growth factor (VEGF)-bound abicipar following single and multiple intravitreal injections of abicipar pegol…
- Trial name
- NCT02859766
- Testing
- Abicipar pegol
- Where
- 18 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergan
Diabetic Macular Edema
Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)
This study is designed to access the safety and efficacy of multiple injections of KH902 in patients with Diabetic Macular Edema (DME).
- Trial name
- Frontier-1 (NCT01324869)
- Testing
- KH902
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Diabetic Macula Edema
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- BUZZARD (NCT04079231)
- Testing
- Brolucizumab, Aflibercept
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
- Trial name
- NCT07275840
- Testing
- IBI302 8mg dose
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Diabetic Macular Edema (DME)
A First-in-human Trial of SZN-8141 in Diabetic Macular Edema
DUET (Cl-8141-1001) is a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics (how the body processes the study drug), and preliminary biological activity of SZN-8141 in people with diabetic macular…
- Trial name
- DUET (NCT07817121)
- Testing
- SZN-8141 for Injection
- Volunteers
- 9 people
- Sponsor
- Surrozen Operating, Inc.
Vitreomacular Adhesion
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion.
- Trial name
- NCT00798317
- Testing
- Ocriplasmin 125µg
- Where
- 48 sites in United States, Belgium and 5 more
- Volunteers
- 326 people
- Sponsor
- ThromboGenics
Leber Hereditary Optic Neuropathy
Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
The goal of this clinical trial is to assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year.
- Trial name
- REFLECT (NCT03293524)
- Testing
- GS010
- Where
- 13 sites in United States, Belgium and 5 more
- Volunteers
- 98 people
- Sponsor
- GenSight Biologics
Anesthesia, Local
A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population
A Phase 3, randomized, active-controlled, study in pediatric subjects. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 ophthalmic solution compared to Proparacaine Hydrochloride Ophthalmic…
- Trial name
- NCT05325853
- Testing
- AG-920, Proparacaine Ophthalmic
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Neovascular Age-related Macular Degeneration
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B.
- Trial name
- NCT05643118
- Testing
- OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Olix Pharmaceuticals, Inc.
Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD
This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.
- Trial name
- AURORA (NCT01157715)
- Testing
- intravitreal injection of KH902
- Where
- 9 sites in China
- Volunteers
- 122 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Proliferative Diabetic Retinopathy
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR).
- Trial name
- CONDOR (NCT04278417)
- Testing
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Where
- 120 sites in United States, Argentina and 14 more
- Volunteers
- 689 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.
- Trial name
- NCT04370379
- Testing
- IBI302 (the first dose level), IBI302 (the second dose level), Aflibercept
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Diabetic Macular Edema
Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema
This study is a multi-center, open, multiple-dose phase Ib/IIa clinical study evaluating the efficacy and safety of BAT5906 injection in patients with diabetic macular edema.
- Trial name
- NCT04772105
- Testing
- 2.5mg of BAT5906, 4.0mg of BAT5906
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Bio-Thera Solutions
Non-Infectious Uveitis of the Posterior Segment of the Eye
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA…
- Trial name
- SPRING (NCT02251938)
- Testing
- DE-109 440 μg
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Exudative Age-Related Macular Degeneration
Efficacy and Safety Study of ESBA1008 Versus EYLEA®
The purpose of this study is to compare the efficacy and safety of ESBA1008 versus EYLEA® in the treatment of exudative age-related macular degeneration.
- Trial name
- NCT01796964
- Testing
- ESBA1008 solution, Aflibercept
- Volunteers
- 173 people
- Sponsor
- Alcon Research
Retinal Vein Occlusion
Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion
This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study.
- Trial name
- FALCON (NCT01809236)
- Testing
- Conbercept
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Vitreous Hemorrhage, Diabetic Retinopathy
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
- Trial name
- NCT00198497
- Testing
- Vitrase
- Where
- 58 sites in Australia, Brazil and 7 more
- Volunteers
- 510 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Age-related Macular Degeneration, Geographic Atrophy
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04643886
- Testing
- GEM103
- Where
- 29 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gemini Therapeutics, Inc.